Evidence map›Paper›PMID 25922728›Full record

ArticleJournal of thoracic disease2015

A meta-analysis comparing hyperfractionated vs. conventional fractionated radiotherapy in non-small cell lung cancer.

Weisan Zhang, Qian Liu, Xifeng Dong, Ping Lei

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of thoracic disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. [The role of surgery for the management of resectable stage III non-small cell lung cancer].Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2016
    Trial
  2. Article
  3. Review
  4. Review
  5. Efficacy of Radiotherapy FLASH-RT: From Treating Lung Cancer to Preventing Pulmonary Fibrosis.Dose-response : a publication of International Hormesis Society
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Weisan Zhang1 Department of Geriatrics, 2 Tianjin Lung Cancer Institute, 3 Department of Hematology-Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Qian Liu1 Department of Geriatrics, 2 Tianjin Lung Cancer Institute, 3 Department of Hematology-Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Xifeng Dong1 Department of Geriatrics, 2 Tianjin Lung Cancer Institute, 3 Department of Hematology-Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Ping Lei1 Department of Geriatrics, 2 Tianjin Lung Cancer Institute, 3 Department of Hematology-Oncology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Tianjin Medical University General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer is the leading cause of cancer-related mortality. Non-small cell lung cancer (NSCLC) accounts for most lung cancer and carries a 5-year survival rate of 15%. The squamous cell carcinoma, large cell carcinoma, and adenocarcinoma are the most common types of NSCLC. The data on long term use of hyperfractionated radiotherapy (HRT) in NSCLC treatment is lacking. We performed a meta-analysis, based on published randomized trials to compare HRT [continuous hyperfractionated accelerated radiotherapy (CHART)/continuous hyperfractionated accelerated radiotherapy weekend less (CHARTWEL)] vs. conventional fractionated (CF) radiotherapy in the treatment of NSCLC.

methodsA systematic search through the bibliographic databases, PubMed, Google Scholar and Cochrane Library was performed till December 2013.

resultsOf 63 studies identified, 3 studies were analyzed. All were randomized studies and included 1,005 patients in total. The pooled results of the studies showed that HRT did not improve overall survival (OS) of patients suffering from NSCLC compared to CF after 2 years (OR, 1.29; 95% CI, 0.98-1.71; P=0.16) and 3 years (OR, 0.55; 95% CI, 0.34-0.87; P=0.22) which was statistically significant. HRT was no better than CF in controlling tumour (OR, 1.40; 95% CI, 1.03-1.91). No significant difference in metastasis free survival (OR, 1.08; 95% CI, 0.83-1.39) and late dysphagia (OR, 1.48; 95% CI, 0.75-2.92) were observed between the two groups.

conclusionsThe results of the present meta-analysis showed that HRT was not significantly better to conventional radiotherapy in NSCLC treatment.

Indexed as

continuous hyperfractionated accelerated radiotherapy (CHART)continuous hyperfractionated accelerated radiotherapy weekend less (CHARTWEL)hyperfractionated radiotherapy (HRT)Non-small cell lung cancer (NSCLC)

Identifiers

PMID25922728
PMCPMC4387426
OpenAlexW308363426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.